Loading...
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast cancer. Recently, based on data showing improvement in progression-free survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in combinat...
Na minha lista:
| Udgivet i: | Breast Care (Basel) |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger GmbH
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4960359/ https://ncbi.nlm.nih.gov/pubmed/27493615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000447284 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|